DBV Technologies (NASDAQ:DBVT) Shares Gap Up – Time to Buy?

DBV Technologies S.A. (NASDAQ:DBVT) gapped up prior to trading on Friday . The stock had previously closed at $23.04, but opened at $24.70. DBV Technologies shares last traded at $24.4450, with a volume of 189,559 shares changing hands.

Wall Street Analysts Forecast Growth

DBVT has been the subject of several research reports. Cantor Fitzgerald set a $48.00 price target on DBV Technologies in a research report on Wednesday, December 17th. Guggenheim reaffirmed a “buy” rating and set a $51.00 target price (up previously from $35.00) on shares of DBV Technologies in a research note on Wednesday, December 17th. Citizens Jmp upped their target price on shares of DBV Technologies from $21.00 to $45.00 and gave the stock a “market outperform” rating in a report on Wednesday, December 17th. Zacks Research upgraded shares of DBV Technologies from a “strong sell” rating to a “hold” rating in a research report on Monday, September 29th. Finally, Wall Street Zen raised shares of DBV Technologies from a “sell” rating to a “hold” rating in a research note on Friday, November 28th. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, DBV Technologies presently has a consensus rating of “Moderate Buy” and an average price target of $35.38.

DBV Technologies Price Performance

The company has a market capitalization of $985.53 million, a PE ratio of -4.75 and a beta of -1.17. The business’s 50 day simple moving average is $17.54 and its 200 day simple moving average is $13.56.

Insider Buying and Selling

In related news, major shareholder Bpifrance Epic sold 2,076,990 shares of the company’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $4.85, for a total value of $10,073,401.50. Following the transaction, the insider directly owned 8,595,472 shares in the company, valued at approximately $41,688,039.20. This represents a 19.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 1.44% of the company’s stock.

Hedge Funds Weigh In On DBV Technologies

Several large investors have recently modified their holdings of DBVT. Vivo Capital LLC purchased a new stake in DBV Technologies in the 2nd quarter valued at about $9,659,000. Nan Fung Trinity HK Ltd. acquired a new stake in shares of DBV Technologies during the second quarter valued at about $340,000. Adage Capital Partners GP L.L.C. acquired a new stake in shares of DBV Technologies during the second quarter valued at about $9,659,000. MPM Bioimpact LLC purchased a new stake in shares of DBV Technologies in the 2nd quarter valued at approximately $9,649,000. Finally, Octagon Capital Advisors LP acquired a new position in shares of DBV Technologies in the 2nd quarter worth approximately $9,315,000. Institutional investors and hedge funds own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.